Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. (BIO) delivers essential innovations in clinical diagnostics and life science research through its global operations. This dedicated news hub provides investors and industry professionals with timely access to official announcements, financial updates, and scientific advancements.
Discover comprehensive collection of press releases covering quarterly earnings, regulatory milestones, product launches, and strategic partnerships. Our curated feed ensures transparent access to BIO's operational developments across its dual focus areas: laboratory-quality diagnostic systems and cutting-edge research tools.
Key updates include innovations in digital PCR technology, quality control solutions for clinical testing, and advancements supporting biopharmaceutical development. Bookmark this page for direct access to primary-source information affecting BIO's market position and research impact.
Bio-Rad Laboratories, Inc. (NYSE: BIO.B) will release its first-quarter 2023 financial results on May 4, 2023, after market close. A conference call is scheduled for 2 PM Pacific Time to discuss these results, with participation details available. Bio-Rad is recognized as a leader in life science research and clinical diagnostics, with a revenue of $2.8 billion in 2022. The company serves a wide range of customers including universities, hospitals, and biotech firms globally. For more information, the company’s Investor Relations section offers access to the webcast of the call. This will provide insights into the company’s performance and strategic direction as it progresses through the fiscal year.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) announced its participation in a fireside chat at Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference. The event is scheduled for Thursday, March 2, 2023, at 11:45 AM Eastern Time (8:45 AM Pacific Time). A live webcast and replay will be available on the Investor Relations section of Bio-Rad's website. With over 70 years of expertise, Bio-Rad leads in life science research and clinical diagnostics, serving various sectors including healthcare and biotechnology. The company had approximately $2.8 billion in revenues in 2022, employing around 8,300 staff worldwide.
Bio-Rad Laboratories (BIO, BIOb) reported Q4 2022 net sales of $730.3 million, down 0.3% from Q4 2021, primarily due to a significant drop in COVID-related revenue. Life Science sales rose 10.1%, while Clinical Diagnostics declined 8.7%. Net income surged to $827.7 million, or $27.78 per share, from a net loss of $1.57 billion in Q4 2021, driven by fair market value changes in equity securities. For FY 2022, total sales decreased 4.1% to $2.8 billion, with a net loss of $3.63 billion. The company projects 6-7% non-GAAP currency-neutral revenue growth in 2023, citing a strong market recovery and operational improvements.
FAQ
What is the current stock price of Bio Rad Labs (BIO)?
What is the market cap of Bio Rad Labs (BIO)?
